Top Story

Janssen licenses two IBD drug candidates to new biopharma company

Janssen licenses two IBD drug candidates to new biopharma company
September 22, 2017

Provention Bio, a new clinical stage biopharmaceutical company launched earlier this year, announced it has in-licensed two clinical-stage inflammatory bowel disease drug candidates from Janssen.

The first, PRV-6527 (formerly JNJ-40346527) is an oral colony stimulating factor-1 receptor (CSF-1R) small molecule inhibitor in development for Crohn’s disease, and the second, PRV-300 (formerly JNJ-42915925/CNTO 3157), is an anti-toll-like receptor 3 (TLR3) monoclonal antibody in development for ulcerative colitis.

Meeting NewsVideo

VIDEO: Addressing the unmet needs of adult ADHD

September 22, 2017
NEW ORLEANS — In this video, Alexandra Khachatryan, MPH, associate director of global health economics & outcomes research at Shire, discusses the importance
In the Journals

Moderate physical activity could prevent one in 12 deaths globally

September 22, 2017
Physical activity of any form — whether a gym workout, walking to work or doing household chores — for 150 minutes per week reduces the risk for mortality…
Meeting News

DETOUR I: Percutaneous bypass procedure successful in long peripheral lesions

September 22, 2017
A novel percutaneous bypass system using the femoral vein as a pathway conferred a high rate of patency with no effect on venous health in patients with very long…
In the Journals

Pain severity, pain self-efficacy cited as predictors of prescription opioid use after musculoskeletal injury

September 22, 2017
Results from this study linked pain severity and pain self-efficacy with prescription opioid use 4 months after musculoskeletal injury. “Pain severity and poor…
More Headlines »
CME CPE CE

Deep Remission, Mucosal Healing, and Top-Down Treatment Strategies in Ulcerative Colitis: An Infographic Journey

Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and…
More »
Original Article

Combined Surgery for Simultaneous Treatment of Congenital Ptosis and Coexisting Strabismus

Journal of Pediatric Ophthalmology and Strabismus, September/October 2017, Volume 54 Issue 5
To evaluate the clinical outcomes of single-stage surgery for treatment of patients with congenital ptosis and…
More »
Resource Centers
Vision Expo West

Vision Expo West

Video
Meeting News

VIDEO: Additional treatment with ALK inhibitor after progression shows promise in non-small cell lung cancer

September 18, 2017
More »
Advertisement
Advertisement